Clinical Trials
16 trialsNCT03934684 2026-05-11
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Phase 4 Completed
NCT01816971 2026-04-21
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
Phase 2 Completed
NCT02203643 2026-04-14
FORTE
University of Turin, Italy
Phase 2 Completed
NCT02405364 2026-04-08
IFM-CRd
University Hospital, Toulouse
Phase 2 Completed
NCT02302495 2026-04-07
IFM2012-03
University Hospital, Lille
Phase 2 Completed
NCT01813227 2026-04-03
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Hackensack Meridian Health
Phase 2 Completed
NCT01572480 2026-03-10
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03275285 2026-02-09
IKEMA
Sanofi
Phase 3 Completed
NCT02969837 2026-01-16
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
University of Chicago
Phase 2 Completed
NCT01665794 2025-12-22
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Chicago
Phase 1/2 Completed
NCT02937571 2025-11-20
High Dose Carfilzomib for Newly Diagnosed Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02199665 2025-11-03
SINE
University of Chicago
Phase 1 Completed
NCT02512926 2025-10-15
POE14-01
Stanford University
Phase 1 Completed
NCT04191616 2025-09-04
SELECT
Amgen
Phase 2 Completed
NCT04813653 2025-07-24
Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells
Tel-Aviv Sourasky Medical Center
Phase 1 Completed
NCT06055075 2025-07-14
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1/2 Completed